2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

1. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of
the World Health Organization diagnostic criteria for polycythemia vera,
essential thrombocythemia, and primary myelofibrosis: Recommendations
from an ad hoc international expert panel. Blood. 2007;110:1092-1097.
2. Tefferi A. How I treat myelofibrosis. Blood. 2011;117:3494-3504.
3. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression
in essential thrombocythemia are significantly influenced by accurate morphologic
diagnosis: An international study. J Clin Oncol. 2011;29:3179-3184.
4. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic
factors for survival in patients with polycythemia vera and essential
thrombocythemia. Am J Med. 2004;117:755-761.
5. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose
aspirin in polycythemia vera. N Engl J Med. 2004;350:114-124.
6. Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk
stratification assessment in essential thrombocythemia. J Clin Oncol. 2008;
26:2732-2736.
7. Passamonti F. Prognostic factors and models in polycythemia vera,
essential thrombocythemia, and primary myelofibrosis. Clin Lymphoma Myeloma
Leuk. 2011;suppl 1:S25-S27.
8. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of
homozygous JAK2 617V�F mutation in patients with polycythemia vera or
essential thrombocythemia. Blood. 2007;110:840-846.
9. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338
patients with polycythemia vera: The impact of JAK2 (V617F) allele burden
and leukocytosis on fibrotic or leukemic disease transformation and vascular
complications. Leukemia. 2010;24:1574-1579.
10. Passamonti F, Elena C, Schnittger S, et al. Molecular and clinical
features of the myeloproliferative neoplasm associated with JAK2 exon 12
mutations. Blood. 2011;117:2813-2816.
11. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis
of post-polycythemia vera and post-essential thrombocythemia myelofibrosis:
A consensus statement from the International Working Group for Myelofibrosis
Research and Treatment. Leukemia. 2008;22:437-438.
12. Passamonti F, Rumi E, Caramella M, et al. A dynamic prognostic model
to predict survival in post-polycythemia vera myelofibrosis. Blood. 2008;111:
3383-3387.
13. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic
model to predict survival in primary myelofibrosis: A study by the IWG-MRT
(International Working Group for Myeloproliferative Neoplasms Research
and Treatment). Blood. 2010;115:1703-1708.
14. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system
for primary myelofibrosis based on a study of the International Working
Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895-2901.
15. Bjorkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk
factors for transformation to acute myeloid leukemia and myelodysplastic
syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011;29:2410-2415.
16. Ruggeri M, Rodeghiero F, Tosetto A, et al. Postsurgery outcomes in
424
REFERENCES
FRANCESCO PASSAMONTI
patients with polycythemia vera and essential thrombocythemia: A retrospective
survey. Blood. 2008;111:666-671.
17. Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy
complications in patients with essential thrombocythemia carrying the JAK2
(617V�F) mutation. Blood. 2007;110:485-489.
18. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: A refined
Dynamic International Prognostic Scoring System for primary myelofibrosis
that incorporates prognostic information from karyotype, platelet count, and
transfusion status. J Clin Oncol. 2011;29:392-397.
19. Tam CS, Abruzzo LV, Lin KI, et al. The role of cytogenetic abnormalities
as a prognostic marker in primary myelofibrosis: Applicability at the
time of diagnosis and later during disease course. Blood. 2009;113:4171-4178.
20. Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk
categorization for overall and leukemia-free survival in primary myelofibrosis:
A single center study of 433 patients. Leukemia. 2011;25:82-88.
21. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients
with poorer survival in primary myelofibrosis based on the burden of
JAK2V617F mutated allele. Blood. 2009;114:1477-1483.
22. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in
primary myelofibrosis, compared to either a higher allele burden or unmutated
status, is associated with inferior overall and leukemia-free survival.
Leukemia. 2008;22:756-761.
23. Alchalby H, Badbaran A, Zabelina T, et al. Impact of JAK2V617Fmutation
status, allele burden and clearance after allogeneic stem cell
transplantation for myelofibrosis. Blood. 2010;116:3572-3581.
24. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their
clinical correlates in polycythemia vera, essential thrombocythemia and
myelofibrosis. Leukemia. 2009; 23:905-911.
25. Pardanani A, Guglielmelli P, Lasho TL, et al. Primary myelofibrosis
with or without mutant MPL: Comparison of survival and clinical features
involving 603 patients. Leukemia. 2011;25:1834-1839.
26. Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary
myelofibrosis predict leukemic transformation and shortened survival: Clinical
evidence for leukemogenic collaboration with JAK2V617F. Leukemia.
Epub 2011 Sept 13.
27. Guglielmelli P, Biamonte F, Score J, et al. EZH2 mutational status
predicts poor survival in myelofibrosis. Blood. 2011;118:5227-5234.
28. Tefferi A, Lasho TL, Patnaik MM, et al. JAK2 germline genetic
variation affects disease susceptibility in primary myelofibrosis regardless of
V617F mutational status: Nullizygosity for the JAK2 46/1 haplotype is
associated with inferior survival. Leukemia. 2010;24:105-109.
29. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic
myeloid metaplasia: A report on 195 cases with a new scoring system. Blood.
1996;88:1013-1018.
30. Tefferi A, Siragusa S, Hussein K, et al. Transfusion-dependency at
presentation and its acquisition in the first year of diagnosis are both equally
detrimental for survival in primary myelofibrosis-prognostic relevance is
independent of IPSS or karyotype. Am J Hematol. 2010;85:14-17.